{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:05:32Z","timestamp":1777421132202,"version":"3.51.4"},"reference-count":27,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To review the pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of rimegepant for treatment of migraine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources<\/jats:title>\n                    <jats:p>A comprehensive PubMed and Cochrane search (1985 to May 2020) was performed utilizing the keywords rimegepant, Nurtec, orally disintegrating tablet, migraine, migraine headache, migraine disorder, calcitonin gene-related peptide, and calcitonin gene-related peptide antagonist. Additional data were obtained from the references of identified articles, manufacturer\u2019s product labeling and website, ClinicalTrials.gov, and governmental sources.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction<\/jats:title>\n                    <jats:p>All English-language trials evaluating oral rimegepant were included for this review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis<\/jats:title>\n                    <jats:p>Rimegepant orally disintegrating tablet (ODT) is Food and Drug Administration approved for the treatment of migraine. According to data from 3 phase 3 randomized controlled trials, rimegepant has been shown to significantly improve freedom from pain at 2 hours after the dose and freedom from the most bothersome symptom 2 hours postdose. Additional outcomes improved include freedom from photophobia and phonophobia at 2 hours postdose and pain relief 2 hours after the dose. Adverse effects of rimegepant include nausea, urinary tract infection, and dizziness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice<\/jats:title>\n                    <jats:p>Orally disintegrating rimegepant provides a novel mechanism of action for the treatment of acute migraine. When patients experience inadequate relief from other therapies, have contraindications to triptans, or are unable to tolerate the adverse effects of triptans, rimegepant is a promising therapeutic option.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Rimegepant ODT is an efficacious migraine treatment option with a novel mechanism of action, convenient dosage form, and limited adverse effect profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1060028020954800","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T05:10:16Z","timestamp":1599714616000},"page":"650-657","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":20,"title":["Rimegepant Orally Disintegrating Tablet for Acute Migraine Treatment: A Review"],"prefix":"10.1177","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1530-7510","authenticated-orcid":false,"given":"Alicia Potter","family":"DeFalco","sequence":"first","affiliation":[{"name":"South College School of Pharmacy, Knoxville, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Lazim","sequence":"additional","affiliation":[{"name":"South College School of Pharmacy, Knoxville, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan E.","family":"Cope","sequence":"additional","affiliation":[{"name":"South College School of Pharmacy, Knoxville, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,9,10]]},"reference":[{"key":"bibr1-1060028020954800","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30322-3"},{"key":"bibr2-1060028020954800","doi-asserted-by":"publisher","DOI":"10.1111\/head.13281"},{"key":"bibr3-1060028020954800","unstructured":"National Institute of Neurological Disorders and Stroke. Migraine information page. Updated December 31, 2019. Accessed May 26, 2020. https:\/\/www.ninds.nih.gov\/Disorders\/All-Disorders\/Migraine-Information-Page"},{"key":"bibr4-1060028020954800","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-018-0617-4"},{"key":"bibr5-1060028020954800","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811090"},{"key":"bibr6-1060028020954800","volume":"25","author":"Peters GL.","year":"2019","journal-title":"Am J Manag Care"},{"key":"bibr7-1060028020954800","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01577"},{"key":"bibr8-1060028020954800","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413500727"},{"key":"bibr9-1060028020954800","doi-asserted-by":"publisher","DOI":"10.1021\/jm3013147"},{"key":"bibr10-1060028020954800","unstructured":"US Food and Drug Administration. FDA approves new treatment for adults with migraine. Published December 23, 2019. Accessed May 21, 2020. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-adults-migraine"},{"key":"bibr11-1060028020954800","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31606-X"},{"key":"bibr12-1060028020954800","unstructured":"A Phase 2\/3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rimegepant in migraine prevention. ClinicalTrials.gov identifier: NCT03732638. Updated April 17, 2020. Accessed June 2, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03732638"},{"key":"bibr13-1060028020954800","doi-asserted-by":"publisher","DOI":"10.2165\/11534920-000000000-00000"},{"key":"bibr14-1060028020954800","unstructured":"Nurtec ODT. Package insert. Biohaven Pharmaceuticals Inc; 2020. Accessed May 8, 2020. https:\/\/www.nurtec.com\/pi"},{"key":"bibr15-1060028020954800","doi-asserted-by":"publisher","DOI":"10.1186\/1129-2377-14-S1-P118"},{"key":"bibr16-1060028020954800","unstructured":"Center for Drug Evaluation and Research. Clinical microbiology\/virology review(s). Published November 12, 2019. Accessed June 5, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/212728Orig1s000ClinPharmR.pdf"},{"key":"bibr17-1060028020954800","unstructured":"BHV3000-303: phase 3, double-blind, randomized, placebo controlled, safety and efficacy trial of BHV-3000 (rimegepant) orally disintegrating tablet (ODT) for the acute treatment of migraine. ClinicalTrials.gov identifier: NCT03461757. Updated March 27, 2020. Accessed June 2, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03461757"},{"key":"bibr18-1060028020954800","unstructured":"BHV3000-302: phase 3: double-blind, randomized, placebo-controlled, safety and efficacy trial of BHV-3000 (rimegepant) for the acute treatment of migraine. ClinicalTrials.gov identifier: NCT03237845. Accessed June 2, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT03237845"},{"key":"bibr19-1060028020954800","unstructured":"Lipton RB, Conway CM, Stock EG, et al. Efficacy, safety, and tolerability of rimegepant 75 mg, an oral CGRP receptor antagonist, for the acute treatment of migraine: results from a phase 3, double-blind, randomized, placebo-controlled trial, study 301. Poster presented at: 60th Annual Scientific Meeting of the American Headache Society; June 30, 2018; San Francisco, CA. Accessed June 2, 2020. https:\/\/www.biohavenpharma.com\/sites\/default\/files\/documents\/Rimegepant-Phase-3-Study-301_AHS-2018-Late-Breaking-Poster-Presentation-1.pdf"},{"key":"bibr20-1060028020954800","doi-asserted-by":"publisher","DOI":"10.1111\/head.1344"},{"key":"bibr21-1060028020954800","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008944"},{"key":"bibr22-1060028020954800","unstructured":"Micromedex Healthcare Series [database online]. Rimegepant. In: RED BOOK Online. IBM Watson Health; 2020. https:\/\/www-micromedexsolutions-com.eu1.proxy.openathens.net\/micromedex2\/librarian\/CS\/7A7918\/ND_PR\/evidencexpert\/ND_P\/evidencexpert\/DUPLICATIONSHIELDSYNC\/21040E\/ND_PG\/evidencexpert\/ND_B\/evidencexpert\/ND_AppProduct\/evidencexpert\/ND_T\/evidencexpert\/PFActionId\/redbook.ShowProductSearchResults?SearchTerm=rimegepant&searchType=redbookGenericName&searchTermId=932854&searchContent=REDBOOK&searchFilterAD=filterADActive&searchFilterRepackager=filterExcludeRepackager&searchPattern=%5Erimegepant and https:\/\/www-micromedexsolutions-com.eu1.proxy.openathens.net\/"},{"key":"bibr23-1060028020954800","unstructured":"Micromedex Healthcare Series [database online]. Ubrogepant. In: RED BOOK Online. IBM Watson Health; 2020. Accessed June 7, 2020. https:\/\/www-micromedexsolutions-com.eu1.proxy.openathens.net\/micromedex2\/librarian\/CS\/7A7918\/ND_PR\/evidencexpert\/ND_P\/evidencexpert\/DUPLICATIONSHIELDSYNC\/21040E\/ND_PG\/evidencexpert\/ND_B\/evidencexpert\/ND_AppProduct\/evidencexpert\/ND_T\/evidencexpert\/PFActionId\/redbook.ShowProductSearchResults?SearchTerm=ubrogepant&searchType=redbookGenericName&searchTermId=932803&searchContent=REDBOOK&searchFilterAD=filterADActive&searchFilterRepackager=filterExcludeRepackager&searchPattern=%5Eub and https:\/\/www-micromedexsolutions-com.eu1.proxy.openathens.net\/"},{"key":"bibr24-1060028020954800","unstructured":"Micromedex Healthcare Series [database online]. Lasmiditan. In: RED BOOK Online. IBM Watson Health; 2020. Accessed July 6, 2020. https:\/\/www-micromedexsolutions-com.eu1.proxy.openathens.net\/micromedex2\/librarian\/CS\/7A7918\/ND_PR\/evidencexpert\/ND_P\/evidencexpert\/DUPLICATIONSHIELDSYNC\/21040E\/ND_PG\/evidencexpert\/ND_B\/evidencexpert\/ND_AppProduct\/evidencexpert\/ND_T\/evidencexpert\/PFActionId\/redbook.ShowProductSearchResults?SearchTerm=lasmiditan&searchType=redbookGenericName&searchTermId=932762&searchContent=REDBOOK&searchFilterAD=filterADActive&searchFilterRepackager=filterExcludeRepackager&searchPattern=%5Elasmidi and https:\/\/www-micromedexsolutions-com.eu1.proxy.openathens.net\/"},{"key":"bibr25-1060028020954800","unstructured":"Micromedex Healthcare Series [database online]. Almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan. In: RED BOOK Online. IBM Watson Health; 2020. Accessed June 7, 2020. https:\/\/www-micromedexsolutions-com.eu1.proxy.openathens.net\/micromedex2\/librarian\/CS\/9457BE\/ND_PR\/evidencexpert\/ND_P\/evidencexpert\/DUPLICATIONSHIELDSYNC\/B7C98C\/ND_PG\/evidencexpert\/ND_B\/evidencexpert\/ND_AppProduct\/evidencexpert\/ND_T\/evidencexpert\/PFActionId\/redbook.ShowCustomListResultsPaged?pageNumber=1&customFileName=&customListMgr=true&customListChanges=false and https:\/\/www-micromedexsolutions-com.eu1.proxy.openathens.net\/"},{"key":"bibr26-1060028020954800","unstructured":"Institute for Clinical and Economic Review. ICER issues final report and policy recommendations on acute treatments for migraine. Published February 25, 2020. Accessed July 14, 2020. https:\/\/icer-review.org\/announcements\/acute_migraine_final_report\/"},{"key":"bibr27-1060028020954800","unstructured":"Nurtec ODT. Savings and support made easy. Accessed June 2, 2020. https:\/\/www.nurtec.com\/savings-support"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020954800","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028020954800","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020954800","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:15:51Z","timestamp":1777374951000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028020954800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,10]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1177\/1060028020954800"],"URL":"https:\/\/doi.org\/10.1177\/1060028020954800","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,10]]}}}